[11C]choline as a potential PET marker for imaging of breast cancer athymic mice

Qi-Huang Zheng, K. Lee Stone, Bruce H. Mock, Kathy Miller, Xiangshu Fei, Xuan Liu, Ji Quan Wang, Barbara E. Glick-Wilson, George W. Sledge, Gary Hutchins

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

[11C]Choline has been evaluated as a potential positron emission tomography (PET) marker for imaging of breast cancer. The biodistribution of [11C]choline was determined at 45 min post iv injection in MCF-7's transfected with IL-1alpha implanted athymic mice and MDA-MB-435 implanted athymic mice. The results showed the uptake of [11C]choline in these tumors was high, 2.0% dose/g in MCF-7's transfected with IL-1alpha implanted mice and 1.8% dose/g in MDA-MB-435 implanted mice; the ratios of tumor/muscle (T/M) and tumor/blood (T/B) were 1.7 (T/M, MCF-7's), 2.1 (T/M, MDA-MB-435) and 6.9 (T/B, MCF-7's), 12.5 (T/B, MDA-MB-435), respectively; the tumor/muscle ratios are moderate, and the tumor/blood ratios are high. The micro-PET imaging of [11C]choline in both breast cancer athymic mice was acquired for 15 min from a MCF-7's transfected with IL-1alpha and/or MDA-MB-435 implanted mouse at 45 min post iv injection of 1 mCi of the tracer using a dedicated high resolution (<3 mm full-width at half-maximum) small FOV (field-of-view) PET imaging system, Indy-PET II scanner, developed in our laboratory, which showed the uptake of [11C]choline in MCF-7's transfected with IL-1alpha tumor or MDA-MB-435 tumor implanted in a nude athymic mouse. These results suggest that [11C]choline may be a potential PET breast cancer imaging agent.

Original languageEnglish
Pages (from-to)803-807
Number of pages5
JournalNuclear Medicine and Biology
Volume29
Issue number8
DOIs
StatePublished - Nov 2002

Fingerprint

Choline
Nude Mice
Positron-Emission Tomography
Breast Neoplasms
Neoplasms
Muscles
Injections

Keywords

  • [C]Choline
  • Breast cancer
  • Carbon-11
  • Positron emission tomography
  • Radiomarker
  • Solid-phase extraction

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Medicine
  • Radiology Nuclear Medicine and imaging

Cite this

[11C]choline as a potential PET marker for imaging of breast cancer athymic mice. / Zheng, Qi-Huang; Stone, K. Lee; Mock, Bruce H.; Miller, Kathy; Fei, Xiangshu; Liu, Xuan; Wang, Ji Quan; Glick-Wilson, Barbara E.; Sledge, George W.; Hutchins, Gary.

In: Nuclear Medicine and Biology, Vol. 29, No. 8, 11.2002, p. 803-807.

Research output: Contribution to journalArticle

Zheng, Qi-Huang ; Stone, K. Lee ; Mock, Bruce H. ; Miller, Kathy ; Fei, Xiangshu ; Liu, Xuan ; Wang, Ji Quan ; Glick-Wilson, Barbara E. ; Sledge, George W. ; Hutchins, Gary. / [11C]choline as a potential PET marker for imaging of breast cancer athymic mice. In: Nuclear Medicine and Biology. 2002 ; Vol. 29, No. 8. pp. 803-807.
@article{d57ab220ff314365bc1fb26dd8115c2f,
title = "[11C]choline as a potential PET marker for imaging of breast cancer athymic mice",
abstract = "[11C]Choline has been evaluated as a potential positron emission tomography (PET) marker for imaging of breast cancer. The biodistribution of [11C]choline was determined at 45 min post iv injection in MCF-7's transfected with IL-1alpha implanted athymic mice and MDA-MB-435 implanted athymic mice. The results showed the uptake of [11C]choline in these tumors was high, 2.0{\%} dose/g in MCF-7's transfected with IL-1alpha implanted mice and 1.8{\%} dose/g in MDA-MB-435 implanted mice; the ratios of tumor/muscle (T/M) and tumor/blood (T/B) were 1.7 (T/M, MCF-7's), 2.1 (T/M, MDA-MB-435) and 6.9 (T/B, MCF-7's), 12.5 (T/B, MDA-MB-435), respectively; the tumor/muscle ratios are moderate, and the tumor/blood ratios are high. The micro-PET imaging of [11C]choline in both breast cancer athymic mice was acquired for 15 min from a MCF-7's transfected with IL-1alpha and/or MDA-MB-435 implanted mouse at 45 min post iv injection of 1 mCi of the tracer using a dedicated high resolution (<3 mm full-width at half-maximum) small FOV (field-of-view) PET imaging system, Indy-PET II scanner, developed in our laboratory, which showed the uptake of [11C]choline in MCF-7's transfected with IL-1alpha tumor or MDA-MB-435 tumor implanted in a nude athymic mouse. These results suggest that [11C]choline may be a potential PET breast cancer imaging agent.",
keywords = "[C]Choline, Breast cancer, Carbon-11, Positron emission tomography, Radiomarker, Solid-phase extraction",
author = "Qi-Huang Zheng and Stone, {K. Lee} and Mock, {Bruce H.} and Kathy Miller and Xiangshu Fei and Xuan Liu and Wang, {Ji Quan} and Glick-Wilson, {Barbara E.} and Sledge, {George W.} and Gary Hutchins",
year = "2002",
month = "11",
doi = "10.1016/S0969-8051(02)00339-6",
language = "English",
volume = "29",
pages = "803--807",
journal = "Nuclear Medicine and Biology",
issn = "0969-8051",
publisher = "Elsevier Inc.",
number = "8",

}

TY - JOUR

T1 - [11C]choline as a potential PET marker for imaging of breast cancer athymic mice

AU - Zheng, Qi-Huang

AU - Stone, K. Lee

AU - Mock, Bruce H.

AU - Miller, Kathy

AU - Fei, Xiangshu

AU - Liu, Xuan

AU - Wang, Ji Quan

AU - Glick-Wilson, Barbara E.

AU - Sledge, George W.

AU - Hutchins, Gary

PY - 2002/11

Y1 - 2002/11

N2 - [11C]Choline has been evaluated as a potential positron emission tomography (PET) marker for imaging of breast cancer. The biodistribution of [11C]choline was determined at 45 min post iv injection in MCF-7's transfected with IL-1alpha implanted athymic mice and MDA-MB-435 implanted athymic mice. The results showed the uptake of [11C]choline in these tumors was high, 2.0% dose/g in MCF-7's transfected with IL-1alpha implanted mice and 1.8% dose/g in MDA-MB-435 implanted mice; the ratios of tumor/muscle (T/M) and tumor/blood (T/B) were 1.7 (T/M, MCF-7's), 2.1 (T/M, MDA-MB-435) and 6.9 (T/B, MCF-7's), 12.5 (T/B, MDA-MB-435), respectively; the tumor/muscle ratios are moderate, and the tumor/blood ratios are high. The micro-PET imaging of [11C]choline in both breast cancer athymic mice was acquired for 15 min from a MCF-7's transfected with IL-1alpha and/or MDA-MB-435 implanted mouse at 45 min post iv injection of 1 mCi of the tracer using a dedicated high resolution (<3 mm full-width at half-maximum) small FOV (field-of-view) PET imaging system, Indy-PET II scanner, developed in our laboratory, which showed the uptake of [11C]choline in MCF-7's transfected with IL-1alpha tumor or MDA-MB-435 tumor implanted in a nude athymic mouse. These results suggest that [11C]choline may be a potential PET breast cancer imaging agent.

AB - [11C]Choline has been evaluated as a potential positron emission tomography (PET) marker for imaging of breast cancer. The biodistribution of [11C]choline was determined at 45 min post iv injection in MCF-7's transfected with IL-1alpha implanted athymic mice and MDA-MB-435 implanted athymic mice. The results showed the uptake of [11C]choline in these tumors was high, 2.0% dose/g in MCF-7's transfected with IL-1alpha implanted mice and 1.8% dose/g in MDA-MB-435 implanted mice; the ratios of tumor/muscle (T/M) and tumor/blood (T/B) were 1.7 (T/M, MCF-7's), 2.1 (T/M, MDA-MB-435) and 6.9 (T/B, MCF-7's), 12.5 (T/B, MDA-MB-435), respectively; the tumor/muscle ratios are moderate, and the tumor/blood ratios are high. The micro-PET imaging of [11C]choline in both breast cancer athymic mice was acquired for 15 min from a MCF-7's transfected with IL-1alpha and/or MDA-MB-435 implanted mouse at 45 min post iv injection of 1 mCi of the tracer using a dedicated high resolution (<3 mm full-width at half-maximum) small FOV (field-of-view) PET imaging system, Indy-PET II scanner, developed in our laboratory, which showed the uptake of [11C]choline in MCF-7's transfected with IL-1alpha tumor or MDA-MB-435 tumor implanted in a nude athymic mouse. These results suggest that [11C]choline may be a potential PET breast cancer imaging agent.

KW - [C]Choline

KW - Breast cancer

KW - Carbon-11

KW - Positron emission tomography

KW - Radiomarker

KW - Solid-phase extraction

UR - http://www.scopus.com/inward/record.url?scp=0036848748&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036848748&partnerID=8YFLogxK

U2 - 10.1016/S0969-8051(02)00339-6

DO - 10.1016/S0969-8051(02)00339-6

M3 - Article

VL - 29

SP - 803

EP - 807

JO - Nuclear Medicine and Biology

JF - Nuclear Medicine and Biology

SN - 0969-8051

IS - 8

ER -